GHRH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
==== MHC class II molecule stabilization - chaperonal function ==== The low pH of lysosomes could cause denaturation or proteolysis of MHC class II molecules. HLA-DM binding to MHC stabilizes and protects from degradation, by covering hydrophobic surfaces. Antigen degradation could also ensue, resulting in an inability to bind to the peptide-binding groove. Thus, HLA-DM is needed to protect proteins against the lysosomal environment.
Manipulation of norepinephrine suggests it may actually play a role in creating a feeling of fatigue. Reboxetine, an NRI, decreased time to fatigue and increased subjective feelings of fatigue. This may be explained by a paradoxical decrease in adrenergic activity led by feedback mechanisms.
Thioesters exhibit electrosteric repulsive forces due to amine functional groups and their size, which prevents aggregation. These electrostatic repulsive forces are weakened by counterions in solution, such as Ca2+ found in seawater. Ca2+ ions are naturally found in seawater due to the weathering of calcareous rocks, and allow for dissolution of the oxide-coated particle at low electrolyte concentrations. This leads to the aggregation of silver nanoparticles onto thioesters in seawater. When aggregation occurs, the silver nanoparticles lose microbial toxicity, but have greater exposure in the environment for larger organisms. These effects have not been completely identified, but may be hazardous to an organism's health via biological magnification.
After prevailing, the player is transported to the Black Mesa staff dormitories, where he is witness to the G-Man's rescue of Alyx Vance. The player is then abandoned by the G-Man and presumably killed by a nuclear explosion that was set off. Candidate Twelve's file is closed due to his influence from the mysterious entity from earlier in the game.
Small integral membrane protein 20 (SMIM20) is a protein that in humans is encoded by the SMIM20 gene. SMIM20 acts as a prohormone to the peptide hormone phoenixin (PNX) which was discovered for the first time in 2013 in rodent sensory ganglia. Two alternate cleavage sites within SMIM20 results in two different phoenixin products, Phoenixin-14 (PNX-14) and Phoenixin-20 (PNX-20). In the study of the evolution of nervous systems, SMIM20 together with NUCB2 have been found to have deep homology across all lineages that preceded creatures with central nervous systems, bilaterians, cnidarians, ctenophores, and sponges as well as in choanoflagellates.
Sources: en.wikipedia.org
When World War II broke out in 1939, the southern African territory of Southern Rhodesia had been a self-governing colony of the United Kingdom for 16 years, having gained responsible government in 1923. It was unique in the British Empire and Commonwealth in that it held extensive autonomous powers (including defence, but not foreign affairs) while lacking dominion status. In practice, it acted as a quasi-dominion, and was treated as such in many ways by the rest of the Commonwealth. Southern Rhodesia's white population in 1939 was 67,000, a minority of about 5%; the black population was a little over a million, and there were about 10,000 residents of coloured (mixed) or Indian ethnicity. The franchise was non-racial and in theory open to all, contingent on meeting financial and educational qualifications, but in practice very few black citizens were on the electoral roll. The colony's Prime Minister was Godfrey Huggins, a physician and veteran of World War I (1914–18) who had emigrated to Rhodesia from England in 1911 and held office since 1933. The territory's contribution to the British cause during World War I had been very large in proportion to its white population, though troops had been mostly raised from scratch as there had been no professional standing army beforehand. Since the start of self-government in 1923, the colony had organised the all-white Rhodesia Regiment into a permanent defence force, complemented locally by the partly paramilitary British South Africa Police (BSAP). The Rhodesia Regiment comprised about 3,000 men, including reserves, in 1938.
=== Parachute mitral valve === Parachute mitral valve occurs when all the chordae tendineae of the mitral valve attach to a single papillary muscle. This causes mitral valve stenosis at an early age. It is a rare congenital heart defect. Although it often causes mitral insufficiency, it may not present any symptoms.
In the cocurrent flow exchange mechanism, the two fluids flow in the same direction. As the cocurrent and countercurrent exchange mechanisms diagram showed, a cocurrent exchange system has a variable gradient over the length of the exchanger. With equal flows in the two tubes, this method of exchange is only capable of moving half of the property from one flow to the other, no matter how long the exchanger is. If each stream changes its property to be 50% closer to that of the opposite stream's inlet condition, exchange will stop when the point of equilibrium is reached, and the gradient has declined to zero. In the case of unequal flows, the equilibrium condition will occur somewhat closer to the conditions of the stream with the higher flow.
Probing protein structure and function: By using amino acids with slightly different size such as O-methyltyrosine or dansyl alanine instead of tyrosine, and by inserting genetically coded reporter moieties (color-changing and/or spin-active) into selected protein sites, chemical information about the protein's structure and function can be measured. Probing the role of post-translational modifications in protein structure and function: By using amino acids that mimic post-translational modifications such as phosphoserine, biologically active protein can be obtained, and the site-specific nature of the amino acid incorporation can lead to information on how the position, density, and distribution of protein phosphorylation effect protein function. Identifying and regulating protein activity: By using photocaged aminoacids, protein function can be "switched" on or off by illuminating the organism. Changing the mode of action of a protein: One can start with the gene for a protein that binds a certain sequence of DNA and, by inserting a chemically active amino acid into the binding site, convert it to a protein that cuts the DNA rather than binding it. Improving immunogenicity and overcoming self-tolerance: By replacing strategically chosen tyrosines with p-nitro phenylalanine, a tolerated self-protein can be made immunogenic. Selective destruction of selected cellular components: using an expanded genetic code, unnatural, destructive chemical moieties (sometimes called "chemical warheads") can be incorporated into proteins that target specific cellular components.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.